Search results
Results from the WOW.Com Content Network
Hyperandrogenism affects 5–10% of women of reproductive age. [11] Hyperandrogenism can affect both men and women but is more noticeable in women since elevated levels of androgens in women may facilitate virilization. Because hyperandrogenism is characterized by elevated male sex hormone levels, symptoms of hyperandrogenism in men are often ...
Sertoli–Leydig cell tumour is a testosterone-secreting ovarian tumor and is a member of the sex cord-stromal tumour group [2] of ovarian and testicular cancers. The tumour occurs in early adulthood (not seen in newborn), is rare, comprising less than 1% of testicular tumours. [ 1 ]
The majority of Leydig cell tumors are found in males, usually at 5–10 years of age or in middle adulthood (30–60 years). Children typically present with precocious puberty. [citation needed] Due to excess testosterone secreted by the tumour, one-third of female patients present with a recent history of progressive masculinization.
Ovarian cancer most often occurs after menopause with 50% of these cancers developing after age 63, the American Cancer Society notes. Symptoms of borderline ovarian tumors are the same as “any ...
An androgen-dependent condition, disease, disorder, or syndrome, is a medical condition that is, in part or full, dependent on, or is sensitive to, the presence of androgenic activity in the body. [ citation needed ]
Ensure women are aware of their cancer profile early. "All women should know their cancer risk profile by the age of 30," Litvack says. "We all need to be in control of our own health, having the ...
Adrenocortical carcinoma (ACC) is an aggressive cancer originating in the cortex (steroid hormone-producing tissue) of the adrenal gland.. Adrenocortical carcinoma is remarkable for the many hormonal syndromes that can occur in patients with steroid hormone-producing ("functional") tumors, including Cushing's syndrome, Conn syndrome, virilization, and feminization.
It can be caused by medications such as gonadotropins, [2] gonadotropin-releasing hormone agonists, nonsteroidal antiandrogens, [3] [4] and selective estrogen receptor modulators, as well as conditions like human chorionic gonadotropin-secreting tumors, complete androgen insensitivity syndrome, and estrogen insensitivity syndrome. [5]